DIABETES Add-on to metformin in T2DM-linagliptin or glimepiride?

被引：2

作者：

Christensen, Mikkel ^{[2
]}

Knop, Filip K. ^{[1
]}

机构：

[1] Univ Copenhagen, Diabet Res Div, Dept Internal Med, Gentofte Hosp, DK-2900 Hellerup, Denmark

[2] Univ Copenhagen, Bispebjerg Hosp, Dept Clin Pharmacol, DK-2400 Copenhagen, Denmark

来源：

NATURE REVIEWS ENDOCRINOLOGY | 2012年 / 8卷 / 10期

关键词：

HYPOGLYCEMIA; ASSOCIATION;

D O I：

10.1038/nrendo.2012.163

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Clinicians are responsible for selecting a suitable second-line treatment for patients with type 2 diabetes mellitus when metformin monotherapy fails. New evidence could aid clinicians in deciding between one of the most commonly used second-line agents, glimepiride, and the recently approved dipeptidyl peptidase 4 inhibitor linagliptin.

引用

页码：576 / 578

页数：3

共 50 条

[21] Efficacy and safety of gemigliptin as add-on therapy in patients with type 2 diabetes inadequately controlled on metformin and glimepiride
Han, Kyung Ah
Yu, Jae Myung
Jang, Hak Chul
Song, Young Duk
Ahn, Kyu Jeung
Oh, Takkeun
Lee, Hyoung Woo
Lee, Daeho
Kim, Jae Taek
Jeong, Choon-hee
Kim, Byoung-joon
Park, Kyong Soo
DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 120 : S125 - S126
[22] Add-on therapies to metformin for type 2 diabetes
Shomali, Mansur
EXPERT OPINION ON PHARMACOTHERAPY, 2011, 12 (01) : 47 - 62
[23] Linagliptin as add-on therapy to insulin for patients with type 2 diabetes
von Websky, Karoline
Reichetzeder, Christoph
Hocher, Berthold
VASCULAR HEALTH AND RISK MANAGEMENT, 2013, 9 : 681 - 694
[24] Empagliflozin (EMPA) for ≥76 Weeks as Add-on to Pioglitazone With or Without Metformin in Patients with Type 2 Diabetes (T2DM)
Kovacs, Christopher S.
Seshiah, Veeraswamy
Merker, Ludwig
Christiansen, Anita Vedel
Roux, Flavien
Salsali, Afshin
Kim, Gabriel
Stella, Peter
Woerle, Hans J.
Broedl, Uli C.
DIABETES, 2014, 63 : A273 - A273
[25] Empagliflozin (EMPA) for ≥76 Weeks As Add-on to Pioglitazone with or without Metformin in Patients with Type 2 Diabetes (T2DM)
Kovacs, Christopher Simon
Seshiah, Veeraswamy
Merker, Ludwig
Christiansen, Anita Vedel
Roux, Flavien
Salsali, Afshin
Kim, Gabriel
Stella, Peter
Woerle, Hans-Juergen
Broedl, Uli C.
ENDOCRINE REVIEWS, 2014, 35 (03)
[26] Empagliflozin as Add-On to Metformin for 24 Weeks Improves Glycemic Control in Patients With Type 2 Diabetes (T2DM)
Haering, Hans-Ulrich
Merker, Ludwig
Seewaldt-Becker, Elke
Weimer, Marc
Meinicke, Thomas
Broedl, Uli C.
Woerle, Hans J.
DIABETES, 2013, 62 : A282 - A282
[27] Empagliflozin as Add-On to Pioglitazone With or Without Metformin Improves Glycemic Control in Patients With Type 2 Diabetes (T2DM)
Kovacs, Christopher
Seshiah, Veeraswamy
Swallow, Ros
Jones, Russell
Rattunde, Henning
Woerle, Hans J.
Broedl, Uli C.
DIABETES, 2013, 62 : A291 - A291
[28] ECONOMIC EVALUATION OF VILDAGLIPTIN COMPARED TO GLIMEPIRIDE AS ADD-ON TO METFORMIN FOR THE TREATMENT OF DIABETES MELLITUS TYPE 2 PATIENTS IN GREECE
Hatzikou, M.
Rombopoulos, G.
Yfantopoulos, J.
VALUE IN HEALTH, 2012, 15 (07) : A501 - A501
[29] COST-UTILITY ANALYSIS OF LIRAGLUTIDE VERSUS GLIMEPIRIDE AS ADD-ON TO METFORMIN IN TYPE 2 DIABETES PATIENTS IN CHINA
Gao, Lan
Zhao, Fei-Li
Li, Shu-Chuen
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2012, 28 (04) : 436 - 444
[30] Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes
Mueller-Wieland, Dirk
Kellerer, Monika
Cypryk, Katarzyna
Skripova, Dasa
Rohwedder, Katja
Johnsson, Eva
Garcia-Sanchez, Ricardo
Kurlyandskaya, Raisa
Sjostrom, C. David
Jacob, Stephan
Seufert, Jochen
Dronamraju, Nalina
Csomos, Katalin
DIABETES OBESITY & METABOLISM, 2018, 20 (11): : 2598 - 2607

← 1 2 3 4 5 →